Mathews Journal of Gastroenterology & Hepatology


Previous Issues Volume 1, Issue 1 - 2016

Research Article Full-Text  PDF  

Patterns of Care Among Patients With Genotype 1 Hepatitis C Virus in Europe

Siva Narayanan1

Corresponding Author: Siva Narayanan, SVP and Global Head, Global Evidence, Value and Access, Ipsos Healthcare, 2020 K Street NW, Suite 410, Washington, DC, 20006, USA, Tel: +1-203-297-1208; Email:[email protected]
Received Date: 06 May 2016 
Accepted Date: 29 Aug 2016 
Published Date: 02 Sep 2016
Copyright © 2016 Narayanan S
Citation: Narayanan S. (2016). Patterns of Care Among Patients With Genotype 1 Hepatitis C Virus in Europe. Mathews J Gastroenterol Hepatol 1(1): 004. 


To assess clinical characteristics and patterns of care among patients with Genotype 1 (G1) Hepatitis C virus (HCV) in EU, a multi-center retrospective chart-review study of HCV patients was conducted in the EU (France/Germany/Italy/Spain/ UK) in 2014 to collect de-identified data on diagnosis, clinical status, and treatment patterns. Physicians were screened for duration of practice (=3yrs) and patient volume (=15 HCV patients/month) and recruited from a large panel to be geographically representative. Medical charts of the next 10 consecutive HCV patients were abstracted. 2067 eligible G1 HCV patients were included in the final analysis (France: 374/Germany: 506/Italy: 412/Spain: 475/UK: 300). Patient characteristics included (France/Germany/Italy/Spain/UK) G1-subtype A (49%/38%/30%/31%/58%) or B (44%/47%/67%/61%/28%); current fibrosis scores: F0: 9%/15%/5%/7%/18%, F1: 18%/24%/24%/24%/29%, F2: 24%/23%/31%/23%/17%, F3: 20%/14%/17%/19%/10%, F4: 28%/5%/20%/22%/17%; latest mean alanine aminotransferase levels:58/90/95/62/73 IU/ mL; patients with viral load >1Million IU/mL: 23%/12%/33%/27%/14%. Treatment patterns included (France/Germany/Italy/ Spain/UK)- currently treated:23%/28%/20%/17%/20%, treatment naïve/never been treated:38%/40%/41%/41%/52%, not currently treated (previous treatment non-responder, discontinued or relapsed, or therapy complete and awaiting sustained viral response): 21%/20%/29%/30%/22%, not currently treated for other reasons: 19%/12%/11%/13%/6%. Disease burden was high in this cohort of G1 HCV patients and only a small proportion of patients were not treated owing to achieving sustained viral response.


HCV; Genotype 1; Europe; Burden; Treatments; SVR.

Creative Commons License

© 2015 Mathews Open Access Journals. All Rights Reserved.

Open Access by Mathews Open Access Journals is licensed under a
Creative Commons Attribution 4.0 International License.
Based On a Work at